You are here: Home » Archives for Clinical Study

King Faisal Specialist Hospital and Research Centre Announces Innovative Clinical Pharmacogenomics

RIYADH, Saudi Arabia, Oct. 24, 2023 (GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the launch of the inaugural phase of its clinical pharmacogenomics service within its Heart Center. This pioneering service leverages the patient's DNA to tailor drug dosages and selections, heralding a new era in healthcare that prioritizes personalized treatment for each individual. This groundbreaking approach is poised to enhance treatment outcomes and reduce potential harm.

KFSH&RC's experts have said that this analysis empowers physicians to prescribe medications customized to each patient, factoring in their unique health conditions and genetic traits. Patients' responses to pharmaceuticals can significantly differ based on their genetic profiles. As a result, what proves effective for one patient may have minimal impact in another. It is worth noting that statistics reveal that 15% of hospital admissions stem from adverse drug reactions, imposing substantial financial and human burdens on healthcare systems across the globe.

This innovative service is a collaborative endeavor between the Centre for Genomic Medicine, Healthcare Information Technology Affairs, and the Pharmaceutical Care Department at KFSH&RC. In its initial phase, this service encompasses six of the most frequently prescribed medications, as determined by hospital data, whose efficacy is known to be influenced by genetic variations.

KFSH&RC has made it clear that it remains committed to expanding the scope of this service progressively, encompassing all hospital departments. This expansion underscores the hospital's unwavering dedication to providing personalized healthcare to every patient, ensuring the utmost level of safety, and minimizing harm, while adhering to the latest globally endorsed scientific practices.

At the Global Health Exhibition held in Riyadh from October 29th to 31st, where KFSH&RC plays a vital role as a strategic health partner, the hospital is set to unveil the innovative service that promises to advance healthcare outcomes in the region.

KFSH&RC stated that it is moving to gradually expand the scope of application of the service to include all medical specialties as part of its commitment to providing personalized health care for each patient at the highest level of safety and prevention of harm and to harness the latest scientifically proven practices around the world.

King Faisal Specialist Hospital and Research Center is considered among the most prominent in the world in providing specialized health care, a pioneer in innovation, and an advanced medical research and education center. It also seeks to develop medical technologies and raise health care worldwide in partnership with prominent local, regional and international institutions. To achieve world–class service in the clinical, research, and educational fields.

Contact information:

kfshrc@mcsaatchi.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9e826983–52ae–4fe5–8579–0cbdfcca9d1c


GLOBENEWSWIRE (Distribution ID 8964787)

Datacubed Health Launches eClinical Platform App in China, Ensuring Full Compliance and Accessibility

New York, New York, Sept. 26, 2023 (GLOBE NEWSWIRE) — Datacubed Health, a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, is excited to announce the official launch of its eClinical platform app in China. This milestone achievement represents a significant step forward for Datacubed Health's commitment to expanding its presence in the Chinese market.

As part of this strategic move, Datacubed Health has joined forces with AppInChina, a renowned leader in Android App Store publication, ensuring seamless deployment of the eClinical platform app in official Android stores across China and the Apple App Store. This partnership guarantees accessibility to a wide range of devices and ecosystems.

Kyle Hogan, President of Datacubed Health, emphasized the importance of this collaboration: “Our partnership with AppInChina has been instrumental in ensuring the smooth launch of our eClinical platform app in China. This strategic alliance allows us to reach a broader audience while maintaining compliance with local regulations, which is essential for our growth in this market.”

In preparation for this momentous launch, Datacubed Health has established a legal entity within China and acquired all necessary commercial and legal licenses and certificates. These crucial steps are a testament to Datacubed Health's commitment to providing secure and regulated services within the Chinese market.

Brett Kleger, CEO of Datacubed Health, stated, “Our investment in establishing a legal presence and obtaining the requisite licenses underscores our dedication to operating ethically and responsibly in China. We are focused on delivering cutting–edge solutions while adhering to local regulations and standards.”

Moreover, Datacubed Health has undertaken comprehensive efforts to ensure full software compliance with Chinese regulations. The eClinical platform app for China has been meticulously customized to align with local requirements and has undergone rigorous testing by local quality assurance teams. This meticulous approach ensures the seamless functioning of the platform while adhering to Chinese network security requirements and restrictions.

Datacubed Health has also bolstered its presence in China by establishing a fully compliant and fault–tolerant Software as a Service (SaaS) infrastructure. The Datacubed China solution is now hosted in AWS Beijing, ensuring data security and reliability for users in the region.

With these key developments in operational, legal, and software compliance, Datacubed Health is well–prepared to provide unmatched support to clinical research efforts in China. The launch of the eClinical platform app represents a significant stride in bridging the gap between global research initiatives and the Chinese healthcare landscape.

In the words of CEO Brett Kleger: “We are thrilled to introduce Datacubed Health's eClinical platform app to the Chinese market. Our partnership with AppInChina, legal entity establishment, and rigorous compliance efforts demonstrate our dedication to providing world–class services to our Chinese users. We look forward to empowering clinical research initiatives in China with our cutting–edge solutions.”

To learn more, we invite you to join us at Booth #24 at the 11th Annual Outsourcing in Clinical Trials Southern California 2023 from September 26–27 in San Diego, California, or visit our website at www.datacubed.com.

About Datacubed Health:

Datacubed Health is a pioneering eClinical technology company built from the ground up by industry veterans who wanted to create a better clinical trial experience for all stakeholders. Our solutions are all infused with neuroeconomic principles designed to be inclusive, drive compliance, and greatly improve retention. We strive to deliver the best experience for you and your patients through ease of use and flexible technology configurable to your needs. Our offerings include a Decentralized Trials Platform, eCOA/ePRO, Patient Engagement, eConsent, Medication Adherence, Televisits, and Geofencing. Learn more at www.datacubed.com.

Media Contact:
Heather Shea
Catalytic Agency for Datacubed Health
heather.shea@catalyticagency.com


GLOBENEWSWIRE (Distribution ID 8926943)

Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa

WEST LAFAYETTE, Ind., Sept. 15, 2023 (GLOBE NEWSWIRE) — A Purdue researcher is taking a giant leap forward in the fight against drug–resistant strains of malaria in developing countries.

Open Philanthropy has awarded $1.38 million to Philip Low to further validate a drug therapy that he and his colleagues have previously shown to successfully treat the disease. Low (rhymes with "now") is Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science.

For years, experts have been concerned about the rise of drug–resistant malaria variants in Southeast Asia and the prospect that one or more of these strains might travel to Africa. A similar event occurred in the 1980s with the emergence of drug resistance to the then–standard treatment of chloroquine, which resulted in millions of deaths.

But Low is working to save lives on both continents by conducting clinical trials to validate previous results and to test whether the number of days of an anti–malaria treatment can be reduced.

While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug–resistant malaria. Trials in Southeast Asia showed that imatinib, when combined with the customary malaria therapy, clears all malaria parasites from 90% of patients within 48 hours and 100% of patients within three days. The patients receiving imatinib were also relieved of their fevers in less than half of the time experienced by similar patients treated with the standard therapy.

Open Philanthropy has awarded Low $600,000 for a larger clinical trial in Southeast Asia to validate his previous trials. The organization has also awarded Low $780,000 to determine whether the usual three–day therapy can be reduced to two days or even one. This work will be focused in the African countries of Kenya and Tanzania where malaria is prominent.

"We found that people in Africa must often walk many miles to obtain treatment for malaria. They will receive three pills, walk all the way home, take one or two pills, start to feel better, and then save the third pill for their next malaria infection," Low said. "When they don't finish the course of treatment, only the most drug–resistant strains of the parasite survive and spread. And that's how people build up drug resistance. So we'd like to eventually be able to cure all patients with just one pill. It would prevent these drug–resistant strains from ever proliferating."

Open Philanthropy is a grantmaking organization whose mission is to use its resources to help others as much as it can, according to the funder.

"This is yet another case of an organization recognizing Philip Low's brilliance, scientific vision and mission to help people in all corners of the world," said Brooke Beier, senior vice president of Purdue Innovates. "The Purdue Research Foundation has been a proud partner in supporting his work, protecting and promoting his intellectual property that is changing lives and making our world a better place to live."

Since 1988, Low has been listed on more than 145 invention disclosures to the Purdue Innovates Office of Technology Commercialization. He has been listed on more than 600 patents in nearly two dozen countries around the world from the U.S. Patent and Trademark Office and international patent organizations. During his tenure at Purdue, Low has been awarded 213 research grants for more than $43.5 million. His work also receives support from the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery.

Imatinib was originally produced by Novartis for the treatment of chronic myelogenous leukemia and other cancers. It works by blocking specific enzymes involved in the growth of cancers.

"When we discovered the ability of imatinib to block parasite propagation in human blood cultures in petri dishes, we initiated a human clinical trial where we combined imatinib with the standard treatment (piperaquine plus dihydroartemisinin) used to treat malaria in much of the world," Low said.

Malaria infects human red blood cells, where it reproduces and eventually activates a red blood cell enzyme that in turn triggers rupture of the cell and release of a form of the parasite called a merozoite into the bloodstream. Low and his colleagues theorized that by blocking the critical red blood cell enzyme, they could stop the infection. The data from initial drug trials have confirmed that.

"Because we're targeting an enzyme that belongs to the red blood cell, the parasite can't mutate to develop resistance "" it simply can't mutate our proteins in our blood cells," Low said. "This is a novel approach that will hopefully become a therapy that can't be evaded by the parasite in the future. This would constitute an important contribution to human health."

The goal, Low said, is to get this into developing countries to save lives. With this new round of funding, he says they're now closer than they've ever been.

About Purdue University

Purdue University is a public research institution with excellence at scale. Ranked among top 10 public universities and with two colleges in the top 4 in the United States, Purdue discovers and disseminates knowledge with a quality and at a scale second to none. More than 105,000 students study at Purdue across modalities and locations, with 50,000 in person on the West Lafayette campus. Committed to affordability and accessibility, Purdue's main campus has frozen tuition 12 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap, including its first comprehensive urban campus in Indianapolis, the new Mitchell E. Daniels, Jr. School of Business, and Purdue Computes, at https://www.purdue.edu/president/strategic–initiatives.

About Purdue Innovates

Purdue Innovates is a unified network at Purdue Research Foundation to assist Purdue faculty, staff, students and alumni in either IP commercialization or startup creation. As a conduit to technology commercialization, intellectual property protection and licensing, startup creation and venture capital, Purdue Innovates serves as the front door to translate new ideas into world–changing impact.

For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at otcip@prf.org. For more information about involvement and investment opportunities in startups based on a Purdue innovation, contact Purdue Innovates at purdueinnovates@prf.org.

Media contact: Steve Martin, sgmartin@prf.org

Sources: Philip Low, plow@purdue.edu

Brooke Beier, blbeier@prf.org

Attachment


GLOBENEWSWIRE (Distribution ID 8923129)

A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — A Curia, uma organizao lder em pesquisa, desenvolvimento e fabricao por contrato, anunciou hoje que sua parceira, Replicate Bioscience, recebeu autorizao IND da FDA e dosou o primeiro participante com RBI–4000, uma vacina autorreplicante (de srRNA) contra a raiva, em um estudo clnico de fase 1 utilizando material clnico desenvolvido como parte da colaborao com a Curia.

A Curia liderou o desenvolvimento do processo, o aumento de escala e a fabricao de acordo com as BPFa do frmaco de srRNA RBI–4000. Com aproximadamente 10.000 bases, este srRNA significativamente maior do que um RNAm linear convencional e, historicamente, tem sido difcil fabric–lo nas escalas necessrias para o desenvolvimento clnico. O desenvolvimento do mtodo analtico da Curia e a qualificao dos ensaios tambm foram fundamentais para a liberao dessa molcula de srRNA.

"A Curia se orgulha de ser pioneira na fabricao dessa nova classe de tecnologia de srRNA ao fornecer o frmaco de srRNA RBI–4000 nossa parceira Replicate para apoiar seu ensaio clnico de fase 1", afirmou Christopher Conway, Presidente de Pesquisa e Desenvolvimento da Curia. "Dedicamo–nos a fornecer solues vantajosas, desde o desenvolvimento at a fabricao de acordo com as BPFa para nossos clientes na rea de RNAm."

Essa nova classe de vacinas de srRNA trazem vrias vantagens em relao s vacinas de RNAm existentes, incluindo a necessidade de dosagens mais baixas e maior tolerabilidade. Esse avano abre tambm a porta a mais inovaes em RNA para uso em vacinas e terapias com menos restries em relao ao tamanho das molculas.

"Nossa colaborao com a Curia nos ajudou a fabricar uma nova classe de RNAs autorreplicantes que tm o potencial de fornecer perfis melhorados de bioatividade, tolerabilidade e eficcia em comparao com outras tecnologias de RNA", disse Nathaniel Wang, PhD., fundador e CEO da Replicate. "A Curia ampliou a escala de um processo para RNAs mais longos, que permitiu a produo em larga escala com rendimentos, pureza e potncia suficientes para apoiar o ensaio clnico de fase 1 da Replicate."

A Curia est comprometida em ser uma parceira preferencial desde a descoberta e desenvolvimento at fabricao e comercializao, fornecendo um conjunto completo de servios de suporte a pequenas e grandes molculas, frmacos, enchimento e acabamento assptico de produtos farmacuticos e testes laboratoriais em todas as fases do ciclo de vida do desenvolvimento de medicamentos.

Sobre a Curia
A Curia, antiga AMRI, uma organizao lder em pesquisa, desenvolvimento e fabricao por contrato, que fornece produtos e servios desde a P&D at a fabricao em escala comercial para clientes farmacuticos e biofarmacuticos. Os quase 4.000 funcionrios da Curia em 29 locais nos Estados Unidos, Europa e sia ajudam seus clientes a progredir da curiosidade cura. Saiba mais em CuriaGlobal.com.

Informaes de contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8921444)

Curia unterstützt die klinische Studie der Phase 1 von Replicate Bioscience mit einem neuartigen RNA-Impfstoff der nächsten Generation

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass sein Partner Replicate Bioscience die IND–Freigabe von der FDA erhalten hat und der erste Teilnehmer mit RBI–4000, einem selbstreplizierenden (srRNA) Tollwut–Impfstoff, in einer klinischen Studie der Phase 1 unter Verwendung von klinischem Material, das im Rahmen der Zusammenarbeit mit Curia entwickelt wurde, geimpft wurde.

Curia fhrte die Prozessentwicklung, das Scale–up und die cGMP–Herstellung des Wirkstoffs srRNA RBI–4000 durch. Mit etwa 10.000 Basen ist diese srRNA deutlich grer als eine herkmmliche lineare mRNA und war in der Vergangenheit nur schwer in dem fr die klinische Entwicklung erforderlichen Umfang herzustellen. Die Entwicklung der analytischen Methode und die Qualifizierung der Assays durch Curia waren ebenfalls entscheidend fr die Freigabe dieses srRNA–Molekls.

"Curia ist stolz darauf, ein Pionier in der Herstellung dieser neuen Klasse von srRNA–Technologie zu sein, indem wir den Wirkstoff RBI–4000 srRNA an unseren Partner Replicate liefern, um ihn bei seiner klinischen Studie der Phase 1 zu untersttzen", sagte Christopher Conway, President, Research & Development, Curia. "Wir sind bestrebt, unseren Kunden im mRNA–Bereich vorteilhafte Lsungen von der Entwicklung bis zur cGMP–Herstellung anzubieten."

Diese neue Klasse von srRNA–Impfstoffen bietet eine Reihe potenzieller Verbesserungen im Vergleich zu den bestehenden mRNA–Impfstoffen, darunter eine geringere Dosierung und bessere Vertrglichkeit. Die Weiterentwicklung erffnet zudem Mglichkeiten fr weitere RNA–Innovationen zur Verwendung in Impfstoffen und Therapeutika mit weniger Beschrnkungen hinsichtlich der Moleklgre.

"Unsere Zusammenarbeit mit Curia half uns bei der Herstellung einer neuen Klasse von selbstreplizierenden RNAs, die das Potenzial haben, im Vergleich zu anderen RNA–Technologien verbesserte Bioaktivitts–, Vertrglichkeits– und Wirksamkeitsprofile zu liefern", so Nathaniel Wang, Ph.D., Grnder und CEO von Replicate. "Curia hat ein Verfahren fr lngere RNAs entwickelt, das eine gro angelegte Produktion mit einer Ausbeute, Reinheit und Wirksamkeit ermglicht, die die klinische Studie der Phase 1 von Replicate untersttzt."

Curia hat sich zum Ziel gesetzt, von der Erforschung und Entwicklung ber die Herstellung bis hin zur Vermarktung ein Partner erster Wahl zu sein, und bietet in jeder Phase des Lebenszyklus der Wirkstoffentwicklung eine umfassende Palette von Dienstleistungen zur Untersttzung von kleinen und groen Moleklen, Wirkstoffen, aseptischem Fill & Finish sowie Labortests.

ber Curia
Curia (ehemals AMRI) ist ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen. Es bietet Pharma– und Biopharma–Kunden Produkte und Dienstleistungen von der Forschung und Entwicklung bis zur kommerziellen Herstellung. Die fast 4.000 Mitarbeiterinnen und Mitarbeiter von Curia an 29 Standorten in den USA, Europa und Asien untersttzen ihre Kunden dabei, von Kreativitt und Neugier zu Behandlungs– und Heilungsmglichkeiten zu gelangen. Mehr Informationen erhalten Sie unter CuriaGlobal.com.

Curia "" Kontaktinformationen:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8921444)

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI–4000, a self–replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia conducted process development, scale–up and cGMP manufacture of srRNA RBI–4000 drug substance. At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development. Curia's analytical method development and qualification of the assays were also critical to the release of this srRNA molecule.

"Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI–4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial," said Christopher Conway, President, Research & Development, Curia. "We are dedicated to providing advantaged solutions from development to cGMP manufacture for our customers in the mRNA field."

This new class of srRNA vaccine offers a number of potential improvements to existing mRNA vaccines, including lower dosage requirements and improved tolerability. The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.

"Our collaboration with Curia helped us manufacture a new class of self–replicating RNAs which have the potential to deliver improved bioactivity, tolerability and efficacy profiles as compared to other RNA technologies,” said Nathaniel Wang, Ph.D., founder and CEO of Replicate. "Curia scaled up a process for longer RNAs that enabled large–scale production at yields, purity and potency to support Replicate's Phase 1 clinical trial."

Curia is committed to being a partner of choice from discovery and development through manufacture and commercialization, providing a full suite of services to support small and large molecule, drug substance, drug product aseptic fill–finish and laboratory testing at every phase of the drug development life cycle.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia's nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8920285)

Curia soutient l'essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d'ARN de nouvelle génération

ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan, a annonc aujourd'hui que son partenaire, Replicate Bioscience, a reu une autorisation de sa demande de nouveau mdicament exprimental (Investigational New Drug, IND) auprs de la FDA et a dos le premier participant avec RBI–4000, un vaccin antirabique base d'ARN auto–rpliquant (ARNar) pour une tude clinique de phase 1 employant du matriel clinique dvelopp dans le cadre de sa collaboration avec Curia.

Curia a men le dveloppement des procds, la mise l'chelle et la fabrication respectant les BPFa de la substance mdicamenteuse base d'ARNar RBI–4000. Comptant environ 10 000 bases, cet ARNar est bien plus grand qu'un ARNm linaire conventionnel et a toujours t difficile fabriquer aux chelles requises pour le dveloppement clinique. Le dveloppement d'une mthode analytique par Curia et la qualification des essais ont aussi jou un rle crucial dans le lancement de cette molcule d'ARNar.

Curia est fire d'tre une pionnire dans la fabrication de cette nouvelle classe de technologie d'ARNar en fournissant la substance mdicamenteuse base d'ARNar RBI–4000 son partenaire Replicate afin de soutenir son essai clinique de phase 1 , a dclar Christopher Conway, prsident de la recherche et du dveloppement chez Curia. Nous nous ddions offrir des solutions avantageuses, depuis le dveloppement jusqu' une fabrication respectant les BPFa, nos clients dans le domaine de l'ARNm.

Cette nouvelle classe d'ARNar apporte de nombreuses amliorations potentielles aux vaccins existants base d'ARNm, notamment des posologies plus basses et une meilleure tolrance. Cet avancement ouvre galement la voie une innovation supplmentaire de l'ARN en vue d'une utilisation dans les vaccins et produits thrapeutiques avec moins de contraintes en ce qui concerne la taille des molcules.

Notre collaboration avec Curia nous a aids fabriquer une nouvelle classe d'ARN auto–rpliquants qui ont le potentiel d'offrir des profils de bio–activit, de tolrance et d'efficacit amliors en comparaison avec les autres technologies d'ARN , a comment Nathaniel Wang, Ph.D., fondateur et PDG de Replicate. Curia a labor un processus pour des ARN plus longs ayant permis une production grande chelle selon des rendements, une puret et une puissance mme de soutenir l'essai clinique de phase 1 de Replicate.

Curia est dtermine tre un partenaire de choix depuis la dcouverte et le dveloppement jusqu' la fabrication et la commercialisation, en fournissant une suite complte de services permettant la prise en charge des activits de remplissage–finition aseptique des produits mdicamenteux, substances mdicamenteuses, petites et grandes molcules, ainsi que des tests en laboratoire, chaque phase du cycle de vie du dveloppement de mdicaments.

propos de Curia
Curia, anciennement AMRI, est une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Bass sur 29 sites travers les tats–Unis, l'Europe et l'Asie, les prs de 4 000 employs de Curia aident les clients de l'entreprise passer de la curiosit la gurison. Pour en savoir plus, rendez–vous sur CuriaGlobal.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8921444)

Lifezone Metals Reports Completion of Tembo Zone Infill Drilling at the Kabanga Nickel Project with 41 m Intersect at 2.07% Ni, including 16.4 m at 2.77% Ni

New York (United States), Dar es Salaam (Tanzania), Aug. 31, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited ("Lifezone Metals" or the "Company") (NYSE: LZM), a modern metals company creating value across the battery metals supply chain from mine to metals production and recycling, is pleased to announce an update on its resource definition drilling programme at its Kabanga Nickel project ("Kabanga") in North–West Tanzania. The Kabanga Nickel project is owned jointly by Lifezone Metals, through its subsidiary Kabanga Nickel Ltd ("KNL") and BHP Billiton (UK) DDS Limited ("BHPB"), forming Tembo Nickel Corporation Limited ("TNCL"), the operating entity, together with the Government of Tanzania.

Infill and extensional drilling at the Tembo Zone, which will support an upcoming Mineral Resource estimate ("MRE") and the Definitive Feasibility Study ("DFS"), was successfully completed in July 2023 using four diamond drill rigs on average. Tembo Zone drilling completed from 2021 through July 2023 (see Figure 1) by TNCL comprised of 49 holes, resulting in a total of 23,748 m of diamond drill core available for geological logging and sampling. A further nine holes for a total of 2,596 m were drilled at the Tembo Zone for metallurgical sampling, plus six geotechnical holes (2,312 m) to support the ongoing DFS. Drill core was logged to capture geological and geotechnical features in the on–site drillhole database, and samples were submitted for analysis to SGS's laboratory in Mwanza, Tanzania.

Highlights from Tembo Zone drilling includes:

  • Hole KL22–10 intersected 41 m at 2.07% Ni, 0.39% Cu, and 0.16% Co, (2.67% NiEq23[1]), including 16.4 m at 2.77% Ni, 0.45% Cu, and 0.23% Co, (3.59% NiEq23),
    (see     Figure 4 and Figure 5).
  • Hole KL22–12 intersected 39.6 m at 2.04% Ni, 0.37% Cu, and 0.13% Co, (2.55% NiEq23), including 19.9 m at 2.83% Ni, 0.44% Cu, and 0.19% Co, (3.53% NiEq23),
    (see     Figure 6 and Figure 7); and
  • Hole KL21–01 intersected 29.7 m at 1.94% Ni, 0.29% Cu, and 0.16% Co, (2.51% NiEq23), including 17.0 m at 2.42% Ni, 0.38% Cu, and 0.21% Co, (3.15% NiEq23).

Lifezone Metals' CEO, Chris Showalter said: "Even after years of exploration and >620 km of drilling to date, the Kabanga orebody continues to showcase its quality differential with world–class nickel grades. The most recent infill drilling at the Tembo Zone ensures we can progress towards an updated Mineral Resource estimate, which is crucial for the Definitive Feasibility Study and ultimately support the mine plan."

Please refer to the Figure in the Press Release as attached or on our website at Lifezone Metals – News – Press Releases

Figure 1 Oblique Long Section of Kabanga Project Mineralisation Zones showing Drilling Eras and Mineralised Intercepts >0.58% NiEq23
(looking north–west)

Infill drilling continues at the North Zone, with five diamond drill rigs in operation since late"'June 2023. Three holes have since been completed and seven are underway (two currently pre–collared only) for a total of 6,626 m of drill core (to 18 August 2023).

Recent highlights from the North Zone infill drilling includes:

  • Hole KN22–03 intersected 52.0 m at 2.37% Ni, 0.25% Cu, and 0.14% Co, (2.85% NiEq23), including 39.8 m at 3.03% Ni, 0.32% Cu, and 0.18% Co, (3.65% NiEq23); and
  • Hole KN22–01A intersected 27.7 m at 2.56% Ni, 0.32% Cu, and 0.22% Co, (3.29% NiEq23).

Gerick Mouton, COO added: "We are working well on the ground with the rigs and local laboratories, and I am pleased to see this package of work for the Tembo Zone infill drilling campaign come together. With these intersects and grades on both Tembo and North Zones it undoubtably underscores Kabanga's immense quality. Other ongoing drilling activities, undertaken by four additional rigs, relate to surface and mine geotechnical and hydrological drilling supporting the DFS designs and water balance."

Since December 2021, TNCL has completed 82 holes for more than 35 km of diamond core drilling at Tembo, North, and Safari (to 18 August 2023).

All field work since December 2021 has been conducted on Special Mining Licence "SML 651 / 2021'.

Table 1 shows composites of assay results received to 18 August 2023 from drilling completed by TNCL since late–2021, with a lower cut–off of 0.58% NiEq23.

Table 1 Composited Assay Results >0.58% NiEq23 for Holes Drilled between
2021""18 August 2023

BHID From To Length Ni Cu Co S Density NiEq23 NiEq23 x length
#
(m) (m) (m) (%) (%) (%) (%) (g/cm3)
* 		(%)
TEMBO ZONE
KL22–10 361.0 402.0 41.0 2.07 0.39 0.16 – 3.93 2.67 110
..includes 363.0 364.0 1.0 0.65 0.07 0.01 – 2.85 0.70
365.0 373.0 8.0 1.29 0.45 0.06 – 3.29 1.65
373.8 380.8 7.0 2.67 0.44 0.20 – 4.37 3.40
381.8 398.2 16.4 2.77 0.45 0.23 – 4.62 3.59
KL22–12 383.0 422.6 39.6 2.04 0.37 0.13 – 3.92 2.55 101
..includes 385.0 393.4 8.4 1.44 0.44 0.06 – 3.24 1.78
397.7 417.6 19.9 2.83 0.44 0.19 – 4.66 3.53
418.3 419.6 1.2 1.45 0.26 0.10 – 3.89 1.83
KL21–01 367.2 396.9 29.7 1.94 0.29 0.16 – 3.00 2.51 74
..includes 370.2 376.3 6.1 2.40 0.28 0.21 – 3.00 3.10
376.9 393.9 17.0 2.42 0.38 0.21 – 3.00 3.15
KL22–14 292.3 321.0 28.7 1.94 0.29 0.16 – 4.10 2.49 72
..includes 295.3 304.2 8.9 1.95 0.30 0.14 – 4.29 2.47
304.9 317.9 13.1 2.53 0.37 0.21 – 4.59 3.27
KL22–01 367.0 395.5 28.5 1.61 0.24 0.14 – 3.00 2.10 60
..includes 369.0 369.3 0.3 1.76 0.11 0.19 – 3.00 2.34
371.3 371.6 0.4 0.59 0.08 0.07 – 3.00 0.82
371.9 372.7 0.7 0.69 0.56 0.08 – 3.00 1.14
373.0 391.6 18.7 2.27 0.33 0.20 – 3.00 2.97
391.9 392.5 0.6 2.04 0.18 0.18 – 3.00 2.62
KL21–02 572.3 596.0 23.7 1.80 0.25 0.17 – 3.00 2.37 56
..includes 572.0 572.3 0.3 1.57 0.07 0.12 – 3.00 1.93
572.3 574.3 2.0 0.65 0.15 0.00 – 3.00 0.72
575.3 575.7 0.4 0.80 0.15 0.06 – 3.00 1.02
576.3 593.6 17.3 2.31 0.31 0.23 – 3.00 3.08
316.3 333.4 17.1 2.24 0.30 0.21 – 3.00 2.94
335.4 335.5 0.1 2.49 0.23 0.21 – 3.00 3.17
KL22–13 398.3 421.3 23.0 1.73 0.27 0.11 – 3.89 2.14 49
..includes

 383.0 384.0 1.0 0.59 0.19 0.01 – 2.86 0.70
384.8 386.3 1.5 0.69 0.58 0.02 – 3.06 0.97
387.0 398.3 11.3 2.44 0.39 0.17 – 4.46 3.07
398.3 413.2 14.9 2.21 0.34 0.14 – 4.33 2.74
416.8 418.3 1.6 1.50 0.17 0.12 – 3.56 1.88
KL22–11A 433.2 464.0 30.8 1.08 0.16 0.09 – 3.54 1.40 43
..includes

 436.2 437.9 1.7 2.39 0.19 0.20 – 4.46 3.01
446.1 457.0 10.9 1.87 0.24 0.16 – 4.13 2.40
459.0 461.0 2.0 0.64 0.07 0.05 – 3.27 0.82
KL22–20 321.6 340.6 19.0 1.65 0.23 0.11 – 3.65 2.04 39
..includes 325.6 337.6 12.0 2.19 0.29 0.15 – 4.13 2.72
KL22–09 221.3 241.0 19.7 1.43 0.27 0.12 – 3.74 1.87 37
..includes 224.3 236.0 11.7 2.02 0.36 0.17 – 4.19 2.63
KL22–11 430.0 457.0 27.0 1.07 0.16 0.07 – 3.44 1.32 36
..includes 434.6 436.6 2.0 0.71 0.19 0.06 – 3.39 0.96
437.5 440.3 2.8 2.73 0.20 0.19 – 4.53 3.33
441.0 448.0 7.0 1.50 0.22 0.10 – 3.76 1.86
449.0 452.3 3.3 1.08 0.19 0.02 – 3.43 1.23
KL23–23 644.3 667.7 23.4 1.18 0.13 0.08 11.73 3.24 1.47 34
..includes 647.3 663.4 16.1 1.54 0.16 0.11 15.22 3.42 1.90
679.0 682.0 3.0 0.71 0.06 0.04 3.77 2.73 0.84
KL22–04 485.4 510.0 24.6 0.96 0.16 0.10 – 3.66 1.31 32
..includes 488.4 502.0 13.6 1.38 0.22 0.15 – 4.06 1.89
KL22–23 274.4 296.0 21.6 0.96 0.12 0.08 – 3.09 1.22 26
..includes 276.8 286.0 9.3 1.50 0.19 0.12 – 3.48 1.91
288.0 290.1 2.1 0.90 0.10 0.07 – 3.06 1.15
291.9 292.2 0.3 1.97 0.11 0.15 – 3.77 2.42
KL23–21 675.2 693.1 17.9 1.12 0.13 0.08 12.03 3.35 1.40 25
..includes 678.2 688.5 10.3 1.69 0.17 0.13 18.22 3.48 2.12
KL22–08 221.0 242.4 21.4 0.86 0.16 0.08 – 3.54 1.15 25
..includes 224.0 225.8 1.8 1.53 0.24 0.16 – 4.34 2.08
226.3 237.4 11.1 1.11 0.21 0.11 – 3.79 1.49
KL22–03 578.5 591.1 12.6 1.45 0.22 0.15 – 3.00 1.94 24
..includes 580.5 591.1 10.6 1.71 0.25 0.17 – 3.00 2.29
591.6 593.0 1.4 1.03 0.29 0.11 – 3.00 1.44
KL22–17 270.7 288.5 17.8 0.98 0.17 0.08 – 3.43 1.28 23
..includes 272.7 285.5 12.8 1.23 0.21 0.10 – 3.63 1.61
KL22–05 428.5 445.1 16.6 0.84 0.18 0.08 – 3.44 1.14 19
..includes 431.5 434.6 3.1 1.93 0.28 0.19 – 4.57 2.57
436.6 438.6 2.0 0.70 0.14 0.07 – 3.38 0.94
439.6 442.1 2.5 0.76 0.11 0.08 – 3.31 1.02
KL23–01 291.5 305.5 14.0 1.03 0.14 0.08 – 3.20 1.32 18
..includes 295.2 301.8 6.6 1.73 0.18 0.14 – 3.64 2.19
KL22–06 380.3 395.0 14.7 0.89 0.14 0.08 – 3.50 1.17 17
..includes 383.3 392.3 9.0 1.25 0.20 0.11 – 3.82 1.64
KL22–19 431.0 445.0 14.0 0.66 0.09 0.04 – 2.97 0.80 11
..includes 433.5 436.6 3.1 1.01 0.12 0.05 – 3.09 1.19
439.2 439.8 0.7 1.09 0.12 0.07 – 3.32 1.33
442.3 443.1 0.9 2.64 0.16 0.17 – 4.22 3.17
468.1 468.4 0.4 1.18 0.04 0.09 – 3.73 1.45
KL23–02 279.0 288.7 9.7 0.93 0.10 0.05 – 2.97 1.11 11
..includes 283.1 285.7 2.6 2.22 0.24 0.12 – 3.74 2.66
KL22–16 280.2 294.6 14.4 0.53 0.12 0.05 – 3.25 0.71 10
..includes 283.2 288.4 5.2 0.97 0.22 0.09 – 3.57 1.32
KL22–15 192.0 203.5 11.5 0.50 0.10 0.04 – 3.15 0.66 8
..includes 195.3 196.6 1.3 1.93 0.45 0.16 – 4.09 2.55
197.4 198.5 1.1 0.96 0.15 0.08 – 3.50 1.24
KL22–24 324.0 330.8 6.8 0.63 0.10 0.02 – 2.93 0.72 5
..includes 326.8 327.8 1.0 2.54 0.25 0.05 – 4.20 2.78
707.4 707.4 0.1 2.15 0.29 0.21 31.00 4.22 2.85
708.3 709.1 0.8 2.33 0.30 0.22 31.00 4.31 3.07
KL22–07 402.3 402.5 0.2 3.70 0.03 0.16 – 3.27 4.15 1
KL22–22 317.0 317.8 0.8 1.31 0.19 0.10 – 3.53 1.68 1
KL23–22 763.5 764.5 1.0 0.68 0.04 0.04 5.84 2.90 0.81 1
NORTH ZONE
KN22–03 238.0 290.0 52.0 2.37 0.25 0.14 – 3.00 2.85 148
..includes 239.0 240.0 1.0 1.10 0.11 0.02 – 3.00 1.20
244.1 283.9 39.8 3.03 0.32 0.18 – 3.00 3.65
KN22–01A 369.3 397.0 27.7 2.56 0.32 0.22 – 3.00 3.29 91
KN22–01 366.1 399.5 33.4 1.96 0.27 0.15 – 3.00 2.49 83
..includes 322.9 323.9 1.0 2.52 0.20 0.17 – 3.00 3.06
360.0 360.5 0.5 19.16 0.59 0.79 – 3.00 21.58
368.8 393.0 24.2 2.43 0.32 0.18 – 3.00 3.07
393.5 396.5 3.0 1.93 0.29 0.19 – 3.00 2.58
KN22–02 434.0 466.2 32.2 1.23 0.19 0.09 – 3.00 1.56 50
..includes 437.2 451.9 14.7 2.52 0.40 0.19 – 3.00 3.21

* Default density of 3.0 g/cm3 used (along with sample length) for assay grade weighting where density results not yet returned from the laboratory
# Table sorted highest to lowest NiEq23 x Length of main composite interval per hole
Composited interval average grades weighted by sample length and density.
Main composite interval permitted to include individual samples <0.58% NiEq23 but only reported if entire interval meets cut–off of 0.58% NiEq23.
Sub–composite intervals break at samples <0.58% NiEq23.

Figure 2 TNCL Geologist Team Inspecting Drill Core from the Tembo Zone. From left to right: Jackline Bahati (Geologist), Innocent Ntabala (Senior Geotechnician), and Marry Mushi (Geologist)

Please refer to the Figure in the Press Release as attached or on our website at Lifezone Metals – News – Press Releases

The current North Zone drilling programme is expected to be complete by mid–September 2023, after which focus will shift to a new drilling programme that has been developed for the currently untested zone between Tembo North and Safari, known as the Safari Link programme.

Drilling in Tembo North and Safari shows that the shallow mineralisation trend is open along strike. The Safari Link drilling programme aims to test for the presence of Tembo–style mineralisation, as signalled by airborne EM/magnetics and ground EM coverage, which shows no significant gaps along strike to the north–east of Tembo.

The Safari Link drilling programme, which covers a strike length of approximately 1.5 km and comprises 62 diamond core drillholes for approximately 34 km of drilling, has been approved by TNCL. This programme (see Figure 3) is expected to require approximately six months to complete with six diamond drill rigs and will proceed in three phases: the first of which will test the presence of mineralisation in the Safari Link Zone, and the subsequent phases will infill as required to increase confidence in the characteristics and volume of any mineralisation that is identified to enable its incorporation into subsequent geological modelling.

Please refer to the Figures in the Press Release as attached or on our website at Lifezone Metals – News – Press Releases

Figure 3 Plan View showing Safari Link Planned Drilling Programme against backdrop of Kabanga Project Mineralisation Zones Drilling Eras and Mineralised Intercepts >0.58% NiEq23 (plan rotated 055 )

Figure 4 Core Photo showing Massive Sulfide Mineralisation in KL22–10
Mineralised Interval 376.14""389.48 m = 13.34 m at 2.56% Ni, 0.44% Cu, and 0.20% Co, (3.28% NiEq23) (includes 0.96 m of internal waste (<0.58% NiEq23) 380.82""""381.78 m (shown by red arrows))

Figure 5 Core Photo showing Massive Sulfide Mineralisation in KL22–10
Mineralised Interval 389.48""398.18 m = 8.7 m at 2.77% Ni, 0.46% Cu, and 0.24% Co, (3.63% NiEq23) (end of mineralised interval shown by red arrow)

Figure 6 Core Photo showing Massive Sulfide Mineralisation in KL22–12
Mineralised Interval 397.7""410.94 m = 13.24 m at 2.84% Ni, 0.43% Cu and 0.19% Co, (3.54% NiEq23)

Figure 7 Core Photo showing Massive Sulfide Mineralisation in KL22–12
Mineralised Interval 410.94""417.57 m = 6.63 m at 2.81% Ni, 0.45% Cu, and 0.19% Co, (3.51% NiEq23) (end of mineralised interval shown by red arrow)

Figure 8 Jumbe Maulid (Geology Superintendent) from TNCL showing Massive Sulphide in Drill Core from Hole KN22–03 at North Zone, which intersected 52.0 m at 2.37% Ni, 0.25% Cu, and 0.14% Co, (2.85% NiEq23)

Additional Information Attached: Kabanga Geological History and MRE Overview

Qualified Person

The exploration results disclosed in this news release were prepared under the supervision of and approved by Ms. Sharron Sylvester, Member of the Australian Institute of Geoscientists (2512), and RPGeo (10125) in the fields of Mining and Mineral Resource Estimation. Ms. Sylvester is employed by OreWin Pty Ltd and engaged by Lifezone Metals Ltd. to act as independent Qualified Person for purposes of Subpart 1300 of Regulation S–K ("S–K 1300") for the Kabanga project. She has appropriate qualifications and sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and has reviewed the technical and scientific data disclosed herein and conducted appropriate verification of the underlying data.

The Mineral Resource estimates discussed in this news release were first published in a Technical Report Summary (TRS) titled "Kabanga 2023 Mineral Resource' dated 30 March 2023 and effective as at 15 February 2023. The reader is encouraged to review the 2023 Kabanga TRS, which is available as Exhibit 15.2 filed with LZM's Form 20"'F on with the Securities and Exchange Commission's EDGAR system (sec.gov) on 11July 2023and is available at the following link: https://sec.gov/Archives/edgar/data/1958217/000121390023030343/ff42023ex96–1_lifezone.htm

About Lifezone Metals

Lifezone Metals (NYSE: LZM) is a modern metals company creating value across the battery metals supply chain from resource to metals production and recycling. Our mission is to provide commercial access to proprietary technology and cleaner metals production through a scalable platform underpinned by our tailored hydromet technology. This technology has the potential to be a cleaner and lower cost alternative to smelting, allowing us to responsibly and cost–effectively provide cleaner metals.

By pairing the Kabanga Project in Tanzania, which we believe is one of the largest and highest–grade undeveloped nickel sulphide deposits in the world, with our proprietary Hydromet Technology, we will work to unlock the value of a key new source of supply to global battery metals markets. We have a long–standing partnership with BHP on the Kabanga Project, with BHP having invested USD100 million, as we work to empower Tanzania to achieve full value creation in–country and become the next premier source of nickel.

www.lifezonemetals.com

Additional Information: Kabanga Geological History and MRE Overview

Geology Overview

The Kabanga nickel deposit is located within the East African Nickel Belt (EANB), which extends approximately 1,500 km along a north–east trend from Zambia to Uganda.

The northern and central sections of the EANB are characterised by a thick package of Paleoproterozoic to Mesoproterozoic metasedimentary rocks, known as the Karagwe""Ankole Belt (KAB), within which occurs a suite of broadly coeval, igneous intrusions that correspond to the Kibaran tectonothermal event (1,350""1,400 Ma).

At the project area, the metasediments, which comprise pelites, sandstones, and quartzites, are overturned steeply dipping (70 to 80 to the west), with a north""north–east strike orientation (025 ) from Main to North, changing to a north–east strike orientation (055 ) from North to Safari (see Figure 9).

The potentially economic nickel–bearing massive sulfides are hosted within igneous chonoliths that are concentrically zoned with a gabbronorite margin and an ultramafic cumulate core. The project comprises six distinct sulfide mineralisation zones, namely (from south–west to north–east) Main, MNB, Kima, North, Tembo, and Safari, which occur over a strike length exceeding 7.5 km.

Kabanga sulfide mineralisation occurs both as:

  • Disseminated to net textured interstitial sulfides within the cumulate core zone of the chonoliths, as well as externally; and
  • Massive and semi–massive sulfide bodies along the side margins of the chonoliths.

The massive sulfides, which comprise dominantly pyrrhotite, with trace–to–15% pentlandite, account for the majority of the Mineral Resource estimates.

Please refer to the Figures in the Press Release as attached or on our website at Lifezone Metals – News – Press Releases

Figure 9 Plan View Schematic of Geology of the Kabanga Area

Exploration/Drilling/History Overview

Exploration at Kabanga has been undertaken in several different phases spanning over 45 years, with more than 621 km of drilling having been completed in total over that time (see Table 2), less than 5% of which was on regional targets. The North and Tembo mineralised zones are the most densely drilled of all the mineralised zones identified to date.

The first drilling programme was undertaken by the United Nations Development Program (UNDP) between 1976 and 1979. Following a ten–year moratorium on foreign company exploration, Sutton Resources (Sutton) entered into several different joint ventures (JV) to explore between 1988""1999, after which Barrick Gold took over control of the project through the purchase of Sutton and progressed through several more drilling programmes independently and within JVs with Glencore. Several studies were completed from 2003 onwards, including scoping and prefeasibility studies, followed by an unpublished draft feasibility study undertaken by the Glencore""Barrick Gold JV in 2014. By the end of 2014, approximately 586 km of diamond drilling had been completed.

In 2019, Kabanga Nickel Ltd (KNL) acquired the project. KNL is jointly owned by LHL (83%) through its 100% entity, Lifezone Limited, with the remaining 17% directly owned by BHP Billiton (UK) DDS Limited (BHPB). KNL owns 84% of the project, with the remaining 16% held by the Government of Tanzania under the terms of a framework agreement.

Since December 2021, KNL has completed 82 holes for more than 35 km of diamond core drilling at Tembo, North, and Safari (up to 18 August 2023) (see Table 2).

Table 2 Holes Completed Since Project First Discovered (to 18 August 2023)

Years Company/Companies Metres Drilled Discovery (purpose)
1976""1979 UNDP Regional Exploration 20,068 Main
1991""1992 Sutton Resources 12,974 Main
1993""1995 Sutton""BHP JV 37,947 North
1997""1999 Sutton""Anglo American JV 56,227 North
2000""2004 Barrick Gold Corporation 39,931 MNB
2005""2008 Glencore""Barrick Gold JV 64,957
81,256
242,347 		North Deep (Scoping Study 1)
Tembo (Scoping Study 2)
Safari / Kima (PFS)
2008""2009
2011""2012
2014 		Glencore""Barrick Gold JV 21,368
5,303
3,320 		North (draft FS)
Regional
Regional and Tembo North
2021""18/8/23 KNL 23,748
768
4,116
4,416
2,312 		Tembo (infill and extension)
Safari (extension)
North (infill)
Tembo and North (metallurgical)
Tembo and North (geotechnical)
Total 621,058

All field work since December 2021 has been conducted on Special Mining Licence "SML 651 / 2021' (see Figure 10 and Figure 11).

Permitting Overview

In Tanzania, minerals and natural resources are state owned and the rights to explore and mine minerals and to use natural resources are obtained from regulatory bodies defined in legislation that have a defined duration and are conditioned.

Mineral rights are held in the form of prospecting licences and mining licences. There are several types of prospecting licences and mining licences, depending on the nature of the minerals being mined and the size of the mine. A Special Mining Licence (SML) is the type of licence required for large scale mining operations ("large scale' being defined as those requiring a capital investment not less than US$100 million), and so this is the type of licence required for Kabanga.

Please refer to the Figures in the Press Release as attached or on our website at Lifezone Metals – News – Press Releases

Figure 10 Location of the Project showing Tenements

Figure 11 Location of the Project showing Detail of SML 651 / 2021

Mineral Resources Overview

Ordinary kriged resource estimates were completed in 2008 as part of the Glencore""Barrick Gold JV prefeasibility study. A thorough independent technical audit of the database, QA/QC, and the resource estimates was completed in 2009. The final resource estimate updates were completed in 2010 following an infill drilling campaign. The 2010 estimates form the basis of the Glencore""Barrick Gold JV 2014 draft feasibility study (unpublished).

Check models were completed by KNL for North and Tembo in 2021 using the same drillhole database as the 2010 estimates with a different interpretation and modelling approach. The 2010 and 2021 models were validated and compared visually and statistically for all grade elements estimated and for density.

In March 2023, the current Mineral Resource estimates (see Table 3) were published in a Technical Report Summary under US SEC Regulation S"'K subpart 1300 rules for Property Disclosures for Mining Registrants (S"'K 1300) (effective date 15 February 2023). This is the first time the Kabanga Mineral Resource estimates have been reported under S"'K 1300 guidelines.

As the Kabanga North and Tembo zones contain multi element mineralisation, a nickel equivalent (NiEq) formula updated for current metal prices, costs and other modifying factors has been used for reporting from the Mineral Resource.

The 2023 nickel equivalent (NiEq23) formula is as follows:

NiEq23 (%) = Ni% + Cu% x 0.411 + Co% x 2.765

The 2023 NiEq cut"'off grade is 0.58% NiEq.

Metal price assumptions used for cut"'off grade determination were $9.50/lb for nickel, $4.00/lb for copper, and $26.00/lb for cobalt.

The Initial Assessment assumes an underground mining rate of 2.2 Mtpa. The mining method is underground stoping with backfill, and the extracted mineralised material will feed into an on"'site concentrator. Concentrate is assumed to be transported to an off"'site hydrometallurgical processing facility to produce final nickel, copper, and cobalt metal, with transport of the final metal to Dar es Salaam and export to markets for sale.

A cash flow analysis was not performed for the Project. The Initial Assessment has been prepared to demonstrate reasonable prospects of economic extraction, not the economic viability of the Mineral Resource estimates. The Initial Assessment is preliminary in nature, it includes Inferred Mineral Resources that are considered too speculative geologically to have modifying factors applied to them that would enable them to be categorised as Mineral Reserves, and there is no certainty that this economic assessment will be realised.

Table 3 Kabanga Mineral Resource Estimates as at 15 February 2023
Based on Metal Prices: $9.50/lb Nickel, $4.00/lb Copper, and $26.00/lb Cobalt

Mineral Resource Classification LHL Tonnage (Mt) Grades Recovery
NiEq23
(%) 		Ni
(%) 		Cu
(%) 		Co
(%) 		Nickel
(%) 		Copper
(%) 		Cobalt
(%)
MAIN
Measured "" "" "" "" "" "" "" ""
Indicated 2.14 2.44 1.92 0.28 0.15 87.2 85.1 88.1
Measured+Indicated 2.14 2.44 1.92 0.28 0.15 87.2 85.1 88.1
Inferred "" "" "" "" "" "" "" ""
MNB
Measured "" "" "" "" "" "" "" ""
Indicated "" "" "" "" "" "" "" ""
Measured+Indicated "" "" "" "" "" "" "" ""
Inferred 0.51 1.98 1.52 0.20 0.13 87.2 85.1 88.1
NORTH
Measured 4.7 3.37 2.64 0.35 0.21 87.2 85.1 88.1
Indicated 11.9 3.80 3.05 0.41 0.21 87.2 85.1 88.1
Measured+Indicated 16.6 3.68 2.93 0.39 0.21 87.2 85.1 88.1
Inferred 12.0 3.29 2.64 0.35 0.18 87.2 85.1 88.1
TEMBO
Measured 4.9 3.03 2.34 0.32 0.20 87.2 85.1 88.1
Indicated 2.2 2.20 1.69 0.22 0.15 87.2 85.1 88.1
Measured+Indicated 7.1 2.77 2.14 0.29 0.19 87.2 85.1 88.1
Inferred 2.1 3.05 2.41 0.31 0.18 87.2 85.1 88.1
OVERALL MINERAL RESOURCE
Measured 9.6 3.20 2.49 0.34 0.21 87.2 85.1 88.1
Indicated 16.3 3.40 2.71 0.36 0.19 87.2 85.1 88.1
Measured+Indicated 25.8 3.33 2.63 0.35 0.20 87.2 85.1 88.1
Inferred 14.6 3.21 2.57 0.34 0.18 87.2 85.1 88.1

  1. Mineral Resources are reported exclusive of Mineral Reserves. There are no Mineral Reserves to report.
  2. Mineral Resources are reported showing only the LHL attributable tonnage portion, which is 69.713% of the total.
  3. Cut"'off uses the NiEq23 using a nickel price of $9.50/lb, copper price of $4.00/lb, and cobalt price of $26.00/lb with allowances for recoveries, payability, deductions, transport, and royalties.
    NiEq23% = Ni% + Cu% x 0. 411 + Co% x 2.765.
  4. The point of reference for Mineral Resources is the point of feed into a processing facility.
  5. All Mineral Resources in the 2023MRE were assessed for reasonable prospects for eventual economic extraction by reporting only material above a cut"'off grade of 0.58% NiEq23.
  6. Totals may vary due to rounding.

Forward–Looking Statements

Certain statements made herein are not historical facts but may be considered "forward–looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended and the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. Forward–looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward–looking statements include, but are not limited to, statements regarding future events, the business combination between GoGreen Investments Corporation ("GoGreen") and Lifezone Holdings Limited ("LHL") that formed Lifezone Metals, the estimated or anticipated future results of Lifezone Metals, future opportunities for Lifezone Metals, including the efficacy of Lifezone Metals' hydromet technology ("Hydromet Technology") and the development of, and processing of mineral resources at, the Kabanga Project, and other statements that are not historical facts.

These statements are based on the current expectations of Lifezone Metals' management and are not predictions of actual performance. These forward–looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lifezone Metals. These statements are subject to a number of risks and uncertainties regarding Lifezone Metals' business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions and other effects of the COVID–19 pandemic; the outcome of any legal proceedings that may be instituted against the Lifezone Metals in connection with the business combination; failure to realize the anticipated benefits of the business combination, including difficulty in integrating the businesses of LHL and GoGreen; the risks related to the rollout of Lifezone Metals' business, the efficacy of the Hydromet Technology, and the timing of expected business milestones; Lifezone Metals' development of, and processing of mineral resources at, the Kabanga Project; the effects of competition on Lifezone Metals' business; the ability of Lifezone Metals to execute its growth strategy, manage growth profitably and retain its key employees; the ability of Lifezone Metals to maintain the listing of its securities on a U.S. national securities exchange; costs related to the business combination; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the "SEC"). The foregoing list of risk factors is not exhaustive. There may be additional risks that Lifezone Metals presently does not know or that Lifezone Metals currently believes are immaterial that could also cause actual results to differ from those contained in forward–looking statements. In addition, forward–looking statements provide Lifezone Metals' expectations, plans or forecasts of future events and views as of the date of this release. Lifezone Metals anticipates that subsequent events and developments will cause Lifezone Metals' assessments to change. However, while Lifezone Metals may elect to update these forward–looking statements in the future, Lifezone Metals specifically disclaims any obligation to do so. These forward–looking statements should not be relied upon as representing Lifezone Metals' assessments as of any date subsequent to the date of this release. Accordingly, undue reliance should not be placed upon the forward–looking statements. Nothing herein should be regarded as a representation by any person that the forward–looking statements set forth herein will be achieved or that any of the contemplated results in such forward–looking statements will be achieved. You should not place undue reliance on forward–looking statements herein, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Certain statements made herein include references to "clean" or "green" metals, methods of production of such metals, energy or the future in general. Such references relate to environmental benefits such as lower green–house gas ("GHG") emissions and energy consumption involved in the production of metals using the Hydromet Technology relative to the use of traditional methods of production and the use of metals such as nickel in the batteries used in electric vehicles. While studies by third parties (commissioned by Lifezone Metals) have shown that the Hydromet Technology, under certain conditions, results in lower GHG emissions and lower consumption of electricity compared to smelting with respect to refining platinum group metals, no active refinery currently licenses Lifezone Metals' Hydromet Technology. Accordingly, Lifezone Metals' Hydromet Technology and the resultant metals may not achieve the environmental benefits to the extent Lifezone Metals expects or at all. Any overstatement of the environmental benefits in this regard may have adverse implications for Lifezone Metals and its stakeholders.

[1] NiEq23 = Ni% + (Cu% * 0.411) + (Co% * 2.765)

Attachment


GLOBENEWSWIRE (Distribution ID 8914329)

Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology

Estudo revelou que o obexelimabe produziu melhora clnica rpida, forte e sustentada, incluindo remisso clnica completa, na maioria dos pacientes com IgG4–RD ativa

Os resultados apoiam o desenvolvimento contnuo do obexelimabe para o tratamento de IgG4–RD e potencialmente outras condies autoimunes mediadas por clulas B

WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacutica global comprometida em se tornar lder no desenvolvimento e comercializao de terapias imunolgicas, anunciou a publicao da Fase 2 do estudo que avalia o obexelimabe para o tratamento de pacientes com a Doena Relacionada IgG4 (IgG4–RD) Com base nos resultados deste estudo, a Fase 3 do estudo em pacientes com IgG4–RD est em andamento para investigar ainda mais a eficcia e a segurana do obexelimabe administrado como uma injeo subcutnea.

A IgG4–RD uma doena fibroinflamatria crnica imunomediada que pode afetar mltiplos rgos, incluindo as principais glndulas salivares, rbitas, glndulas lacrimais, pncreas, rvore biliar, pulmes, rins e retroperitnio. Cerca de 20.000 pacientes so diagnosticadas com IgG4–RD somente nos Estados Unidos. Apesar da crescente visibilidade da doena, ainda h necessidade de mais pesquisas e opes teraputicas eficazes para indivduos que vivem com essa doena debilitante.

Em todo o mundo, o uso de glicocorticoides amplamente considerado o padro de tratamento para o tratamento de IgG4–RD. No momento no existe nenhum tratamento aprovado para esta condio. Embora comumente usados, os glicocorticoides e as terapias de depleo de clulas B disponveis raramente levam a remisses livres de tratamento a longo prazo e esto associados a um alto risco de toxicidade para os pacientes. Tais terapias tambm prejudicam as respostas vacinais, incluindo as do SARS–CoV–2 e da gripe.

Em um estudo piloto prospectivo, aberto, de brao nico e centro nico para avaliar a eficcia e a segurana do obexelimabe no tratamento de pacientes com IgG4–RD (registro clinicaltrials.gov NCT02725476), o obexelimabe demonstrou forte melhora no IgG4–RD Responder Index, uma medio da atividade da doena, inibindo a funo das clulas B, sem esgotar as clulas B.

O manuscrito publicado, intitulado "Obexelimab for the Treatment of Patients with IgG4–Related Disease: An Open–Label, Single–Arm, Pilot Study to Evaluate Efficacy, Safety, and Mechanism of Action," est disponvel online e constar na edio de agosto do The Lancet Rheumatology 2023;5(8) [E428–E429].

As principais concluses do artigo so as seguintes:

  • O Obexelimabe apresentou melhora clnica rpida, forte e sustentada, incluindo remisso completa (pontuao 0 no IgG4–RD Responder Index), na maioria dos pacientes com IgG4–RD ativa.
  • Durante o tratamento com obexelimabe, foram observadas redues nas clulas B circulantes, incluindo plasmablastos, sem evidncia de morte celular.
  • Alm disso, a reduo das clulas B circulantes e o rpido retorno aos nveis quase normais aps a descontinuao do tratamento, sugerem que o obexelimabe pode levar ao sequestro de clulas B em rgos linfoides ou na medula ssea.
  • O Obexelimabe foi bem tolerado. A maioria dos eventos adversos relacionados ao tratamento foram de grau 1 ou 2, com os eventos adversos mais comuns sendo eventos relacionados infuso gastrointestinal, a maioria dos quais foram leves.

"Os resultados so um passo significativo na compreenso dos mecanismos subjacentes da Doena Relacionada IgG4; abrindo caminho para estratgias de tratamento mais direcionadas", disse John Stone, MD, MPH, Professor de Medicina da Harvard Medical School e Edward A. Fox Chair em Medicina do Mass General Hospital. "Nossa equipe tem a honra de ter nossa pesquisa reconhecida pelo The Lancet Rheumatology, e somos imensamente gratos aos pacientes que participaram deste estudo inovador."

Sobre o Obexelimab

O obexelimabe um anticorpo monoclonal humanizado de Fase 3 bifuncional, no citoltico, de investigao que imita a ao dos complexos antgeno–anticorpo por ligao a CD19 e FcRIIb para inibir a atividade das clulas da linhagem B. Em vrios estudos clnicos em fase inicial de diversas doenas autoimunes, 198 indivduos foram tratados com obexelimabe. Nestes estudos clnicos, o obexelimabe demonstrou inibio eficaz da funo das clulas B sem a reduo das clulas, e um efeito encorajador no tratamento de pacientes com vrias doenas autoimunes. Zenas adquire da Xencor, Inc. direitos mundiais exclusivos do obexelimabe.

Mais informaes sobre a Fase 3 (INDIGO) do estudo para o tratamento de Doenas Relacionadas IgG4 esto disponveis em clinicaltrials.gov: NCT05662241.

Sobre a Zenas BioPharma

A Zenas BioPharma uma empresa biofarmacutica mundial comprometida em se tornar lder global no desenvolvimento e comercializao de terapias imunolgicas para pacientes em todo o mundo. Com desenvolvimento clnico e operaes globais, a Zenas est avanando um portflio global profundo e equilibrado das melhores teraputicas autoimunes em potencial em reas de alta necessidade mdicas, atendendo aos requisitos de valor do dinmico ambiente global de sade. O pipeline da empresa continua a crescer por meio da nossa estratgia de desenvolvimento de negcios de sucesso. Nossa experiente equipe de liderana e rede de parceiros de negcios impulsionam a excelncia operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenas autoimunes e raras. Para mais informao sobre a Zenas BioPharma, visite www.zenasbio.com e siga–nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mdia:
Joe Farmer, Presidente e COO
Zenas BioPharma
IR@zenasbio.com


GLOBENEWSWIRE (Distribution ID 8886118)

Zenas BioPharma gibt die Veröffentlichung von Daten zu einer Phase-2-Studie mit Obexelimab, einem Prüfpräparat zur Behandlung der IgG4-assoziierten Erkrankung (IgG4-RD), im Fachjournal „The Lancet Rheumatology“ bekannt

Die Studie ergab, dass Obexelimab bei den meisten Patientinnen und Patienten mit aktiver IgG4–RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschlielich einer vollstndigen klinischen Remission fhrte

Die Ergebnisse untersttzen die Weiterentwicklung von Obexelimab zur Behandlung von IgG4–RD und mglicherweise anderen B–Zell–vermittelten Autoimmunerkrankungen

WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, ein weltweit ttiges Biopharmaunternehmen, das sich der Aufgabe verschrieben hat, eine fhrende Position in der Entwicklung und Vermarktung von immunbasierten Therapien einzunehmen, gibt die Verffentlichung von Ergebnissen aus einer Phase–2–Studie mit Obexelimab im Fachjournal "The Lancet Rheumatology" bekannt. In der Studie wird Obexelimab fr die Behandlung von Patientinnen und Patienten mit lgG4–assoziierter Erkrankung (IgG4–RD) untersucht. Auf der Grundlage der Ergebnisse dieser Studie wird derzeit eine Phase–3–Studie mit Patientinnen und Patienten mit IgG4–RD durchgefhrt, um die Wirksamkeit und Sicherheit von Obexelimab, das als subkutane Injektion verabreicht wird, weiter zu untersuchen.

IgG4–RD ist eine chronische, immunvermittelte fibroinflammatorische Erkrankung, die mehrere Organe betreffen kann, darunter die groen Speicheldrsen, die Augenhhlen, die Trnendrsen, die Bauchspeicheldrse, die Gallenwege, die Lunge, die Nieren und das Retroperitoneum. Allein in den USA wurde bei etwa 20.000 Menschen IgG4–RD diagnostiziert. Trotz der zunehmenden Anerkennung der Erkrankung besteht nach wie vor ein Bedarf an weiterer Forschung und wirksamen Behandlungsoptionen fr die Patientinnen und Patienten, die an dieser belastenden Krankheit leiden.

Weltweit gilt die Anwendung von Glukokortikoiden als Standardbehandlung von IgG4–RD. Es gibt keine zugelassenen Behandlungsoptionen fr diese Erkrankung. Glukokortikoide und verfgbare Therapien zur Reduktion von B–Zellen werden zwar hufig eingesetzt, fhren aber selten zu langfristigen, behandlungsfreien Remissionen und sind bei diesen Patient*innen mit einem hohen Toxizittsrisiko verbunden. Solche Therapien beeintrchtigen zudem die Impfantwort, unter anderem bei den Impfstoffen gegen SARS–CoV–2 und Influenza.

In einer prospektiven, offenen, einarmigen Pilotstudie in einem einzelnen Prfzentrum zur Untersuchung der Wirksamkeit und Sicherheit von Obexelimab bei der Behandlung von Patient*innen mit IgG4–RD (clinicaltrials.gov–Registrierung NCT02725476) zeigte Obexelimab eine deutliche Verbesserung des IgG4–RD–Responder–Index, einer Kennzahl fr die Krankheitsaktivitt. Obexelimab hemmt die B–Zell–Funktion, ohne die B–Zellen zu dezimieren.

Das verffentlichte Manuskript mit dem Titel "Obexelimab for the Treatment of Patients with IgG4–Related Disease: An Open–Label, Single–Arm, Pilot Study to Evaluate Efficacy, Safety, and Mechanism of Action" (Obexelimab zur Behandlung von Patient*innen mit lgG4–assoziierter Erkrankung: eine offene einarmige Pilotstudie zur Beurteilung von Wirksamkeit, Sicherheit und Wirkmechanismus) ist online verfgbar und erscheint in der Augustausgabe von The Lancet Rheumatology 2023;5(8) [E428–E429].

Die wichtigsten Erkenntnisse des Papiers sind:

  • Obexelimab fhrte bei den meisten Patient*innen mit aktiver IgG4–RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschlielich einer vollstndigen Remission (Score 0 im IgG4–RD–Responder–Index).
  • Whrend der Behandlung mit Obexelimab wurde eine Verringerung der zirkulierenden B–Zellen, einschlielich der Plasmablasten, beobachtet, ohne dass es Anzeichen fr einen Zelltod gab.
  • Darber hinaus deutet die Reduktion der zirkulierenden B–Zellen und die schnelle Rckkehr zu Werten annhernd im Normbereich nach Absetzen der Behandlung darauf hin, dass Obexelimab zu einer Sequestrierung von B–Zellen in den lymphatischen Organen oder im Knochenmark fhren kann.
  • Obexelimab wurde gut vertragen. Die Mehrzahl der behandlungsbedingten unerwnschten Ereignisse war von Grad 1 oder 2. Die hufigsten unerwnschten Ereignisse waren gastrointestinale infusionsbedingte Ereignisse, von denen die meisten leicht waren.

"Unsere Ergebnisse sind ein wichtiger Schritt, um ein tieferes Verstndnis der zugrunde liegenden Mechanismen der IgG4–assoziierten Erkrankung zu erlangen, und sie ebnen den Weg fr gezieltere Behandlungsstrategien", so John Stone, MD, MPH, Professor fr Medizin, Harvard Medical School und Edward A. Fox Chair in Medicine, Mass General Hospital. "Unser Team fhlt sich geehrt, dass unsere Forschung von The Lancet Rheumatology anerkannt wird, und wir sind den Patient*innen, die an dieser bahnbrechenden Studie teilgenommen haben, beraus dankbar."

ber Obexelimab

Obexelimab ist ein bifunktionaler, nicht–zytolytischer, humanisierter monoklonaler Antikrper in Phase 3 der klinischen Prfung, der die Wirkung von Antigen–Antikrper–Komplexen nachahmt, indem er CD19 und FcRIIb bindet, um die Aktivitt von Zellen der B–Linie zu hemmen. In mehreren klinischen Studien im Frhstadium zu verschiedenen Autoimmunerkrankungen wurden 198 Probanden mit Obexelimab behandelt. In diesen klinischen Studien zeigte Obexelimab eine wirksame Hemmung der B–Zell–Funktion, ohne die Zellen zu dezimieren, und erzielte einen ermutigenden Behandlungseffekt bei Patient*innen mit verschiedenen Autoimmunkrankheiten. Zenas hat die weltweiten Exklusivrechte an Obexelimab von Xencor, Inc. erworben.

Weitere Informationen ber die Phase–3–Studie (INDIGO) zur Behandlung der IgG4–assoziierten Erkrankungen finden Sie unter clinicaltrials.gov: NCT05662241.

ber Zenas BioPharma

Zenas BioPharma ist ein weltweit ttiges Biopharmazieunternehmen, das sich zum Ziel gesetzt hat, fhrend in der Entwicklung und Vermarktung von immunbasierten Therapien fr Patientinnen und Patienten in aller Welt zu werden. Zenas ist weltweit in der klinischen Entwicklung ttig und verfgt ber ein umfassendes und ausgewogenes globales Portfolio potenzieller First– und Best–in–Class–Autoimmuntherapeutika in Bereichen mit hohem ungedecktem medizinischem Bedarf und erfllt gleichzeitig die Wertanforderungen des dynamischen globalen Gesundheitsumfelds. Die Pipeline des Unternehmens wchst durch unsere erfolgreiche Geschftsentwicklungsstrategie weiter an. Unser erfahrenes Fhrungsteam und unser Netzwerk von Geschftspartnern sorgen fr operative Spitzenleistungen, um potenziell transformative Therapien bereitzustellen, die das Leben von Menschen mit Autoimmunerkrankungen und seltenen Krankheiten verbessern. Weitere Informationen ber Zenas BioPharma finden Sie unter www.zenasbio.com und folgen Sie uns auf Twitter unter @ZenasBioPharma und LinkedIn.

Anleger– und Medienkontakt:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com


GLOBENEWSWIRE (Distribution ID 8886118)